Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
St. Joseph's Healthcare Hamilton
This study is designed to support the optimal use of mTOR-inhibitor by providing data for the safe and effectiveness use with sirolimus. This study will take into account effectiveness aspects such as malignancy-free survival cancer by reducing the overall exposure to calcineurin inhibitor.
Age
18–50
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male patients ≤ 50 years in their post renal transplant follow-up;
Biopsy confirmed prostate cancer;
Stable renal function with GFR ≥ 40 mL/min.
You may not be if
Patients with metastatic disease;
Uncontrolled hyperlipidemia;
Proteinuria \> 500 mg/day;
Biopsy evidence of acute rejection within the past 3 months;
Existence of any surgical or medical condition, other than the current transplant, which in the opinion of the investigator might significantly alter the absorption, distribution, metabolism or excretion of study medication;
Patients with mental illness;
Inability to cooperate or communicate with the investigator or unable to complete self administered questionnaires.
Clareo Health | Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
